LB Pharmaceuticals Appoints William Kane and Rekha Hemrajani to Board of Directors.

LB Pharmaceuticals has appointed William Kane and Rekha Hemrajani to its Board of Directors, effective September 10, 2025. The company believes their expertise in finance, business development, product commercialization, and corporate strategy will enhance its Board of Directors as it advances its lead product candidate, LB-102, into Phase 3 and Phase 2 clinical trials for acute schizophrenia and bipolar depression, respectively. LB-102 has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the US.

LB Pharmaceuticals Inc. (NASDAQ: LBRX) has recently appointed William Kane and Rekha Hemrajani to its Board of Directors, effective September 10, 2025. These appointments come at a crucial time as the company prepares to advance its lead product candidate, LB-102, into Phase 3 trials for acute schizophrenia and Phase 2 trials for bipolar depression in early 2026 LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

William Kane, who serves as the President and CEO of Uniquity Bio, brings over three decades of biopharmaceutical leadership to the Board. He has a proven track record in commercializing new therapies, having held senior roles at companies such as Anthos Therapeutics, Karuna Therapeutics, BioXcel Therapeutics, Allergan, and Pfizer. Kane's experience in launching multiple leading branded therapeutics, including Namzaric, Vraylar, and Ubrelvy, positions him to provide valuable insights into the commercialization of LB-102 LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

Rekha Hemrajani, who currently serves on the boards of directors of ALX Oncology, BioAge Labs, and MaxCyte, brings significant financial and operational expertise to the Board. She has held executive roles at Aravive, Arcus Biosciences, and RAPT Therapeutics, as well as served as CFO of Sagimet Biosciences. Hemrajani's experience in financial operations and corporate governance will be instrumental in guiding LB Pharmaceuticals through its clinical trials and potential regulatory approvals LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

The appointments of Kane and Hemrajani come as LB Pharmaceuticals aims to leverage the broad therapeutic potential of LB-102. LB-102, a Phase 3-ready oral small molecule and a methylated derivative of amisulpride, demonstrated statistically significant benefits versus placebo in a Phase 2 trial for acute schizophrenia. The company believes LB-102 has the potential to become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

These strategic appointments are part of LB Pharmaceuticals' broader mission to bring safer, more effective neuropsychiatric treatments to patients. The company is building a pipeline that includes potential expansion opportunities for LB-102 into major depressive disorder, predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis, and agitation, as well as bipolar mania and cognitive impairment associated with schizophrenia LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2].

References

LandBridge, NRG Plan Data-Backed Power Hub In Texas^[1] https://newsable.asianetnews.com/markets/landbridge-nrg-plan-data-backed-power-hub-in-texas-articleshow-0wz7u4d
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani^[2] https://www.stocktitan.net/news/LBRX/lb-pharmaceuticals-strengthens-board-of-directors-with-appointments-nj22n23hv51c.html